Cancer pharmacogenomics: International trends

Yasuko Yamayoshi, Emiko Iida, Yusuke Tanigawara

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


It is well known that inter-individual variability exists in the responses to many drugs. Many nongenetic factors, such as age, sex, diet, and organ function, are known to affect the therapeutic effects of drugs. However, recent advances in pharmacogenomics have revealed that genetic polymorphisms also significantly influence both the efficacy and the toxicity of drugs. Mutations in the genes encoding drug-metabolizing enzymes, transporters, and target molecules may alter their expression, activity, or affinity to drugs, thereby influencing the drugs' pharmacokinetics and pharmacodynamics. Numerous studies have reported on the correlations between therapeutic outcomes and polymorphisms in drug-metabolizing enzymes, transporters, target molecules, and DNA repair enzymes. These pharmacogenomic discoveries are expected to be useful for the individualization and optimization of cancer chemotherapy.

Original languageEnglish
Pages (from-to)5-13
Number of pages9
JournalInternational Journal of Clinical Oncology
Issue number1
Publication statusPublished - 2005 Feb


  • Drug response
  • Drug toxicity
  • Genetic polymorphisms
  • PK/PD
  • Pharmacogenomics
  • Therapeutic effect

ASJC Scopus subject areas

  • Surgery
  • Hematology
  • Oncology


Dive into the research topics of 'Cancer pharmacogenomics: International trends'. Together they form a unique fingerprint.

Cite this